Free Trial

Pro-Dex (PDEX) Stock Price, News & Analysis

Pro-Dex logo
$47.53 +2.35 (+5.20%)
Closing price 04:00 PM Eastern
Extended Trading
$47.55 +0.02 (+0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pro-Dex Stock (NASDAQ:PDEX)

Key Stats

Today's Range
$45.06
$47.66
50-Day Range
$39.00
$48.99
52-Week Range
$17.81
$70.26
Volume
58,766 shs
Average Volume
37,752 shs
Market Capitalization
$155.00 million
P/E Ratio
16.98
Dividend Yield
N/A
Price Target
$56.00
Consensus Rating
Buy

Company Overview

Pro-Dex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

PDEX MarketRank™: 

Pro-Dex scored higher than 50% of companies evaluated by MarketBeat, and ranked 580th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pro-Dex has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pro-Dex's stock forecast and price target.
  • Earnings Growth

    Earnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pro-Dex is 16.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pro-Dex is 16.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.61.

  • Price to Book Value per Share Ratio

    Pro-Dex has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Pro-Dex's valuation and earnings.
  • Percentage of Shares Shorted

    10.97% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pro-Dex has recently increased by 39.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pro-Dex does not currently pay a dividend.

  • Dividend Growth

    Pro-Dex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.97% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pro-Dex has recently increased by 39.56%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pro-Dex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Pro-Dex this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for PDEX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pro-Dex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.28% of the stock of Pro-Dex is held by institutions.

  • Read more about Pro-Dex's insider trading history.
Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

PDEX Stock Analysis - Frequently Asked Questions

Pro-Dex's stock was trading at $46.75 on January 1st, 2025. Since then, PDEX stock has increased by 1.7% and is now trading at $47.53.

Pro-Dex, Inc. (NASDAQ:PDEX) issued its quarterly earnings results on Thursday, May, 1st. The medical instruments supplier reported $0.98 EPS for the quarter, topping the consensus estimate of $0.47 by $0.51. The medical instruments supplier earned $17.41 million during the quarter, compared to analysts' expectations of $17.70 million. Pro-Dex had a trailing twelve-month return on equity of 29.08% and a net margin of 14.61%.

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

Last Earnings
5/01/2025
Today
7/16/2025
Next Earnings (Estimated)
9/04/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED/DENTAL - SUPP
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PDEX
CIK
788920
Employees
140
Year Founded
N/A

Price Target and Rating

High Price Target
$56.00
Low Price Target
$56.00
Potential Upside/Downside
+22.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.80
Trailing P/E Ratio
16.34
Forward P/E Ratio
22.87
P/E Growth
N/A
Net Income
$2.13 million
Net Margins
14.61%
Pretax Margin
19.32%
Return on Equity
29.08%
Return on Assets
16.19%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
2.73
Quick Ratio
1.45

Sales & Book Value

Annual Sales
$64.12 million
Price / Sales
2.33
Cash Flow
$0.95 per share
Price / Cash Flow
48.28
Book Value
$9.03 per share
Price / Book
5.07

Miscellaneous

Outstanding Shares
3,261,000
Free Float
1,712,000
Market Cap
$149.16 million
Optionable
Not Optionable
Beta
0.19

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:PDEX) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners